Unity Biotechnology, Inc. (UBX) financial statements (2021 and earlier)

Company profile

Business Address 3280 BAYSHORE BOULEVARD
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments98127171
Cash and cash equivalents183715
Short-term investments8090156
Other undisclosed current assets322
Total current assets:101129173
Noncurrent Assets
Operating lease, right-of-use asset24 
Property, plant and equipment13176
Long-term investments and receivables183 
Long-term investments183 
Restricted cash and investments111
Other noncurrent assets 12
Total noncurrent assets:55228
TOTAL ASSETS:156151181
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:755
Accounts payable355
Accrued liabilities755
Employee-related liabilities564
Settlement liabilities  2
Other undisclosed accounts payable and accrued liabilities(8)(11)(11)
Other undisclosed current liabilities81212
Total current liabilities:141717
Noncurrent Liabilities
Long-term debt and lease obligation59  
Long-term debt, excluding current maturities25  
Operating lease, liability34 
Liabilities, other than long-term debt 133
Deferred rent credit 132
Other liabilities  0
Other undisclosed noncurrent liabilities(34) 2
Total noncurrent liabilities:59134
Total liabilities:733121
Stockholders' equity
Stockholders' equity attributable to parent, including:83121161
Common stock000
Additional paid in capital422367325
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(339)(245)(163)
Other undisclosed stockholders' equity attributable to parent(0)(1)(1)
Total stockholders' equity:83121161
TOTAL LIABILITIES AND EQUITY:156151181

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Operating expenses(94)(90)(79)
Operating loss:(94)(90)(79)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
04(0)
Net loss:(94)(85)(80)
Other undisclosed net income (loss) attributable to parent(0)33
Net loss available to common stockholders, diluted:(94)(82)(76)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(94)(85)(80)
Comprehensive loss:(94)(85)(80)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)33
Comprehensive loss, net of tax, attributable to parent:(94)(82)(76)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: